the ether-a-go-go related gene is a pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel is associated with cardiac arrhythmias and rhythmic excitability of the pituitary. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). The potassium channel is probably composed of a homo- or heterotetrameric complex of pore-forming alpha subunits that can associate with modulating beta subunits. Heteromultimer with Kv11.2 and Kv11.3. Interacts with ALG10B. Heteromultimer with KCNE1 and KCNE2. Defects in Kv11.1 are the cause of long QT syndrome type 2 (LQT2), a heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress. Deafness is often associated with LQT2. Defects in Kv11.1 are the cause of short QT syndrome type 1 (SQT1), a heart disorder characterized by idiopathic persistently and uniformly short QT interval on ECG in the absence of structural heart disease in affected individuals. They cause syncope and sudden death. Four isoforms of the human protein are produced by alternative splicing. Isoform 3 has no channel activity by itself, but modulates channel characteristics when associated with isoform 1. Note: This description may include information from UniProtKB.
Cellular Component: cell surface; nuclear envelope; perinuclear region of cytoplasm; plasma membrane; voltage-gated potassium channel complex
Molecular Function: delayed rectifier potassium channel activity; identical protein binding; inward rectifier potassium channel activity; protein binding; protein homodimerization activity; two-component sensor activity; ubiquitin protein ligase binding; voltage-gated potassium channel activity
Biological Process: cardiac muscle contraction; potassium ion homeostasis; regulation of membrane potential; regulation of the rate of heart contraction by hormone; synaptic transmission; two-component signal transduction system (phosphorelay)
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.